

FORM PTO-1390(modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 10-95)		ATTORNEY'S DOCKET NUMBER 30695
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C., 371		U.S. APPLICATION NO. (IF KNOWN), SEE 37 CFR 10/ 551 717
INTERNATIONAL APPLICATION NO. PCT/IL2004/000286	INTERNATIONAL FILING DATE 29 March 2004	PRIORITY DATE CLAIMED 1 April 2003
TITLE OF INVENTION TAK1-MEDIATED INHIBITION OF OSTEOGENESIS		
APPLICANT(S) FOR DO/EO/US (1) Dan GAZIT; (2) Gadi PELLED; (3) Gadi TURGEMAN; (4) Andrea HOFFMANN; (5) Gerhard GROSS; (6) Claas WODARCZYK; (7) Kristin VERSCHUEREN		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO.US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).</p> <p>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(3)(2)) <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(3)(2)).</p> <p>7. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</p> <p>8. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. </p> <p>9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).</p> <p>10. <input checked="" type="checkbox"/> An <u>unsigned</u> oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>11. <input type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</p> <p>12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 13 to 18 below concern document(s) of information included:		
<p>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>15. <input type="checkbox"/> A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.</p> <p>16. <input type="checkbox"/> A substitute specification.</p> <p>17. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>18. <input type="checkbox"/> Certificate of Mailing by Express Mail</p> <p>19. <input type="checkbox"/> The sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing</p> <p>20. <input checked="" type="checkbox"/> Other items or information: PCT REQUEST; PRELIMINARY AMENDMENT</p> <p>21. <input checked="" type="checkbox"/> 59 pages of specification (including Abstract page)</p> <p>22. <input checked="" type="checkbox"/> 17 sheets of drawings</p> <p>23. <input type="checkbox"/> ____ pages of sequence listing</p> <p>24. <input checked="" type="checkbox"/> 76 total pages</p>		

U.S. APPLICATION NO. (IF KNOWN), See 37 CFR 10/551717	INTERNATIONAL APPLICATION NO. PCT/IL2004/000286	ATTORNEY'S DOCKET NUMBER 30695
---	---	--

THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

FOR:	Column 1 No. FILED	Column 2 No. EXTRA	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
			Rate	Fee	Rate	Fee
Basic National Stage Fee				\$ 150		\$ 300
National Stage Search Fee				\$ 250		\$ 500
National Stage Examination Fee				\$ 100		\$ 200
National Stage Application Size Fee (Per 50 Pages Over 100)			x \$ 125	\$	x \$250	\$
Multiple Dependent Claim			x \$ 180	\$	x \$ 360	\$
Total Claims*	25 - 20=	5	x \$ 25	\$ 125	x \$50	\$
Independent Claims*	4 - 3=	1	x \$100	\$ 100	x \$200	\$
* (If the difference in Column 1 is less than "0", enter "0" in Column 2)			TOTAL	\$725	TOTAL	\$

Please charge my deposit account No. 50-1407 in the amount of \$725.

A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No 50-1407.
A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 CFR 1.16.

Any patent application processing fees under 37 CFR 1.17.

The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to deposit Account No. 50-1407.
A duplicate copy of this sheet is enclosed.

Any patent application processing fees under 37 CFR 1.17.

Any filing fees under 37 CFR 1.16 for presentation of extra claims.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Martin Moynihan
PRTSI, Inc.
P.O. Box 16446
Arlington, Virginia 22215
USA

Tel: (703) 598-7851 Fax: (703) 415-4864

Martin Moynihan
SIGNATURE

Martin Moynihan

NAME

40,338

REGISTRATION NUMBER

10/3/05

DATE